DS
FDMT icon

David Shaw’s 4D Molecular Therapeutics FDMT Stock Holding History

David Shaw’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$590K Buy
44,354
+20,324
+85% +$198K ﹤0.01% 4101
2026
Q1 		$224K Sell
24,030
-87,792
-79% -$764K ﹤0.01% 4164
2025
Q4 		$839K Buy
111,822
+101,722
+1,007% +$1.03M ﹤0.01% 3643
2025
Q3 		$87.8K Sell
10,100
-11,035
-52% -$66K ﹤0.01% 4360
2025
Q2 		$78.4K Sell
21,135
-4,205
-17% -$14.8K ﹤0.01% 4141
2025
Q1 		$81.8K Sell
25,340
-10,693
-30% -$50.4K ﹤0.01% 4036
2024
Q4 		$201K Sell
36,033
-3,117
-8% -$24.5K ﹤0.01% 4086
2024
Q3 		$423K Sell
39,150
-4,276
-10% -$71K ﹤0.01% 3794
2024
Q2 		$912K Sell
43,426
-322
-0.7% -$8.08K ﹤0.01% 3251
2024
Q1 		$1.39M Buy
+43,748
New +$1.12M ﹤0.01% 2880
2023
Q2 		– Sell
-81,457
Closed -$1.4M – 4330
2023
Q1 		$1.4M Sell
81,457
-107,932
-57% -$2.1M ﹤0.01% 2930
2022
Q4 		$4.21M Buy
189,389
+179,345
+1,786% +$2.77M ﹤0.01% 2254
2022
Q3 		$81K Sell
10,044
-15,626
-61% -$142K ﹤0.01% 4628
2022
Q2 		$179K Buy
+25,670
New +$250K ﹤0.01% 4581

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

David Shaw's FDMT Position: Q2 2026 in Review

David Shaw increased its 4D Molecular Therapeutics (FDMT) stake by 85% in Q2 2026, buying an estimated $198K and bringing the position to 44,354 shares worth $590K. The position accounts for ﹤0.01% of the portfolio, ranked #4101.

David Shaw first reported a position in FDMT in Q2 2022 and has held it in 14 quarters since. The position peaked at $4.21M in Q4 2022. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • David Shaw held 44,354 shares of 4D Molecular Therapeutics worth $590K as of Q2 2026.
  • David Shaw bought 20,324 4D Molecular Therapeutics shares in Q2 2026, an estimated $198K.
  • 4D Molecular Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4101 holding.
  • David Shaw first reported a position in 4D Molecular Therapeutics in Q2 2022 and has held it in 14 quarters since.
  • David Shaw's 4D Molecular Therapeutics position peaked at $4.21M in Q4 2022.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.